Suggested by Gary Kucher about 3 years ago

Regulatory challenges: The use of psychedelic therapies for mental health treatment is still largely unregulated in most countries, which creates a number of challenges for companies trying to develop and market these therapies.

Lack of research and clinical data: While there is a growing body of research suggesting that psychedelic therapies can be effective for treating a range of mental health conditions, there is still much that is unknown, such as the role of belief or placebo in outcomes. This lack of data can make it difficult for companies to gain regulatory approval and for clinicians to feel comfortable using these therapies.

Stigma and social acceptance: Psychedelic therapies still face a great deal of stigma and controversy, which can make it challenging for companies to gain public acceptance and investment.

High cost of care: Psychedelic-assisted therapy can be expensive, and many people cannot afford it. This creates a barrier to access for those who have the largest need for treatment. Additionally, insurance coverage for psychedelic therapy is limited, making it difficult for many to receive the care they need.

Intellectual property challenges: With so much innovation happening in the psychedelic mental health industry, there are a number of intellectual property challenges emerging, including disputes over patents and ownership of research.

Diversity and inequality: There is a growing concern about the lack of diversity and representation in clinical trials and psychedelic care, with marginalized communities and those of lower socioeconomic status being disproportionately impacted by mental health issues and at increased risk of being unable to access these therapies.

Safety concerns: Psychedelic therapies can be powerful tools, but they are not without risks. Ensuring the safety of patients and clinicians during these therapies is a top priority for the industry, and best practices and regulations are needed to minimize risk.

Unknowns: Limited understanding of why some individuals do not respond or respond adversely to treatment.

Potential harm: Risk of inducing psychosis or an unmanageable spiritual emergence in some individuals during and after treatment.

Misaligned incentives: Corporate models prioritizing shareholder return over the quality of client care or the well-being of all stakeholders involved in care delivery and in local communities.

Harm reduction for those seeking self care solutions for mental health issues.

...more at psychedelicsvision.com